Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Cracks in cola kingdom: India's duopoly faces biggest test in decades
India's cola market is undergoing a significant transformation, moving beyond the traditional Coca-Cola vs. PepsiCo rivalry. Reliance's Campa revival ignited a price war, while ITC's new premium, sugar-free coconut cola signals a shift towards health, premiumization, and niche offerings. This evolving landscape caters to health-conscious consumers seeking alternatives, indicating a more dynamic and diversified future for the Indian beverage sector.
Cupid shares gain 2% as firm raises FY27 guidance, expects Q1 revenue to top Rs 150 crore
Cupid shares gained 2% as the company anticipates a record Q1 FY27 revenue exceeding Rs 150 crore. Buoyed by strong market visibility, Cupid has boosted its FY27 revenue forecast to over Rs 660 crore. This optimistic outlook is fueled by diversified business, expanding global opportunities in healthcare, and growth in its condom and lubricant portfolios. The company is also making strides in its IVD business, signaling robust future potential.
A new-age thirst for beverages is emerging as a key force in India's consumer goods market
Beverage industry in India: Indian companies are seeing strong growth in drinks like coffee, ready-to-drink options, and protein beverages. Younger consumers are driving this trend, seeking convenience and health. Companies are expanding their offerings to meet this demand. This shift presents significant opportunities for future expansion in the Indian beverage market.
Open to 4-5 acquisitions, but at sensible valuations: Ameera Shah, promoter and executive chairperson, Metropolis Healthcare
Metropolis Healthcare is set for its next growth phase. The diagnostic chain will focus on genomics and specialty diagnostics. Strategic acquisitions will also play a key role. The company aims to expand services beyond pathology. This strategy will drive future growth and strengthen its market position.
Alembic Pharma gets USFDA tentative nod for generic prostate cancer drug
Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic version of Darolutamide tablets, targeting prostate cancer treatment. The approval is for the 300 mg strength. The drug is a generic version of Nubeqa Tablets. The robust market potential for these tablets suggests promising future growth for Alembic.
From oncology to obesity, Pfizer bets big on India for its next growth wave
Pfizer is focusing on India for future growth. The company plans to launch new medicines quickly and at affordable prices. India is seen as a crucial market for new treatments in cancer, obesity, and vaccines. Pfizer is also working on local clinical studies for future drug launches.
Reliance Industries shares in focus as Mukesh Ambani eyes satellite foray to take on Starlink
Reliance Industries is evaluating a multi-billion-dollar entry into satellite communications, focusing on low Earth orbit networks under Jio Platforms. The initiative aims to strengthen India’s strategic capabilities amid rising global competition, with discussions underway on technology partnerships, orbital slots and potential acquisitions as the company explores long-term opportunities in future.
RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September
RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.
Top Gainers & Losers on Mar 12: Piramal Pharma, Tejas Networks, Apollo Tyres, PG Electroplast among top losers
The Indian stock market extended its losses on March 12, with the Nifty 50 and Sensex down 1% and 1.08%. Tensions in the Middle East affected investor sentiment, particularly impacting auto stocks, while broader markets showed some positive movement.
Top Gainers & Losers on Feb 26: Tejas Networks, KSB, Mankind Pharma, Tata Motors, Finolex Cables among top gainers
The Indian stock market remained largely unchanged on February 26, with the Nifty 50 up 0.06% at 25,496 and the S&P BSE Sensex flat at 82,248. Broader markets showed mixed results, while US stocks rallied on Nvidia's strong earnings, boosting Asian markets as well.